Trial Profile
COMPARATIVE, RANDOMISED, SINGLE-DOSE, CROSSOVER, 3-WAY BIOAVAILABILITY STUDY OF DAPAGLIFLOZIN 10 mg FORMULATIONS IN HEALTHY VOLUNTEERS UNDER FED CONDITIONS
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Dapagliflozin
- Indications Cardiovascular disorders; Chronic heart failure; COVID 2019 infections; Heart failure; Kidney disorders; Myocardial infarction; Obesity; Prediabetic state; Renal failure; Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Acronyms KRK-001
- Sponsors KRKA
- 05 Oct 2021 Status changed from recruiting to completed.
- 02 Feb 2021 New trial record